Bliss GVS Pharma disclosed voting results for postal ballot on two independent director appointments.
Both resolutions passed with 99.72% approval from votes polled, covering 49.14% of outstanding shares.
E-voting period was April 10 to May 9, 2026, with scrutinizer report submitted on May 11, 2026.
No invalid votes were recorded across all shareholder categories in the voting process.